Q3 2024 Quest Diagnostics Inc Earnings Call Transcript
Key Points
- Quest Diagnostics Inc (DGX) reported strong total revenue growth of 8.5% in the third quarter, with 4.2% organic growth driven by new customer wins and expanded business with physicians and hospitals.
- The company completed three acquisitions in the third quarter, including LifeLabs in Canada, which provides a strong foundation for expansion in a growing market with favorable demographics.
- Quest Diagnostics Inc (DGX) saw double-digit revenue growth in advanced diagnostics, particularly in brain health, women's health, cardiometabolic health, and autoimmune disorders.
- The consumer-facing platform, questhealth.com, grew total revenues by more than 40%, with a significant increase in repeat customer rates.
- The company is on track to complete eight acquisitions this year, which are expected to contribute to growth, profitability, and returns in the future.
- The integration of recent acquisitions, including LifeLabs, is expected to initially be dilutive to operating margins, with profitability expanding over several quarters.
- Quest Diagnostics Inc (DGX) faced challenges from weather and an IT outage, which negatively impacted volume and operating margins by approximately 50 basis points in the third quarter.
- The company anticipates a negative impact on revenues and EPS in the fourth quarter due to Hurricane Milton.
- Wage inflation remains above historical norms, posing a challenge to cost management despite efforts to offset it through automation and AI.
- The operating margin is expected to be down versus the prior year due to the integration of LifeLabs and other headwinds, including weather and IT disruptions.
Welcome to the Quest Diagnostics third quarter 2024 conference call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and the question-and-answer session that will follow are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited.
I'd now like to turn the call over to Shawn Bevec, Vice President of Investor Relations for Quest Diagnostics. Sir, please go ahead.
Thank you, and good morning. I'm joined by Jim Davis, our Chairman, Chief Executive Officer and President; and Sam Samad, our Chief Financial Officer.
During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation to non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
